These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19089342)

  • 1. Modulation of cGMP in heart failure: a new therapeutic paradigm.
    Boerrigter G; Lapp H; Burnett JC
    Handb Exp Pharmacol; 2009; (191):485-506. PubMed ID: 19089342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble guanylate cyclase: a potential therapeutic target for heart failure.
    Gheorghiade M; Marti CN; Sabbah HN; Roessig L; Greene SJ; Böhm M; Burnett JC; Campia U; Cleland JG; Collins SP; Fonarow GC; Levy PD; Metra M; Pitt B; Ponikowski P; Sato N; Voors AA; Stasch JP; Butler J;
    Heart Fail Rev; 2013 Mar; 18(2):123-34. PubMed ID: 22622468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of nitric oxide-sensitive guanylyl cyclase.
    Friebe A; Koesling D
    Circ Res; 2003 Jul; 93(2):96-105. PubMed ID: 12881475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure.
    Preedy MEJ; Baliga RS; Hobbs AJ
    J Cardiovasc Pharmacol; 2020 May; 75(5):370-384. PubMed ID: 31498237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure.
    Baliga RS; Preedy MEJ; Dukinfield MS; Chu SM; Aubdool AA; Bubb KJ; Moyes AJ; Tones MA; Hobbs AJ
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7428-E7437. PubMed ID: 30012589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.
    Bice JS; Burley DS; Baxter GF
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):269-82. PubMed ID: 24572031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
    Hoffmann LS; Chen HH
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Aug; 387(8):707-18. PubMed ID: 24927824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-type natriuretic peptide regulation of guanosine-3',5'-cyclic monophosphate production in human endothelial cells.
    Rautureau Y; Gowers I; Wheeler-Jones CP; Baxter GF
    Auton Autacoid Pharmacol; 2010 Jul; 30(3):185-92. PubMed ID: 20085572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Pharmacological Strategies to Increase cGMP.
    Buglioni A; Burnett JC
    Annu Rev Med; 2016; 67():229-43. PubMed ID: 26473417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Modulation of Guanylate Cyclase Pathway Activity-Mechanism and Clinical Implications.
    Grześk G; Nowaczyk A
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34200064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
    Castro LR; Schittl J; Fischmeister R
    Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway.
    Miraglia E; De Angelis F; Gazzano E; Hassanpour H; Bertagna A; Aldieri E; Revelli A; Ghigo D
    Reproduction; 2011 Jan; 141(1):47-54. PubMed ID: 20965947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria.
    Wen JF; Cui X; Jin JY; Kim SM; Kim SZ; Kim SH; Lee HS; Cho KW
    Circ Res; 2004 Apr; 94(7):936-43. PubMed ID: 14988225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
    Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and regulation of soluble guanylate cyclase.
    Derbyshire ER; Marletta MA
    Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
    Friebe A; Sandner P; Seifert R
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1237-46. PubMed ID: 26486926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating cGMP to treat lung diseases.
    Ghofrani HA; Grimminger F
    Handb Exp Pharmacol; 2009; 191(191):469-83. PubMed ID: 19089341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.